News
The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.
The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback